BACKGROUND: Carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6) inhibits anoikis and affects the malignant phenotype of cancer cells. In this study, we analyzed CEACAM6 as a gene that is highly upregulated in colon cancer tissues, and examined the assertion that CEACAM6 might be a suitable candidate tumor marker for the diagnosis of colon cancer. METHODS: CEACAM6 gene expression in human colon tissues was performed by tissue microarray and analyzed using RT-PCR (each of normal and tumor tissue, n=40) and immunohistochemical and clinicopathological (colon cancer patients, n=143) analyses. RESULTS: CEACAM6 transcriptional and translational levels were significantly upregulated in human tumor tissues compared to non-tumor regions, and clinicopathological analysis revealed a significant correlation between CEACAM6 protein expression and Dukes' stage (p<0.001). High expression levels of CEACAM6 were significantly associated with lower overall survival (p<0.001) and shorter recurrence-free survival (p<0.001). We demonstrated that knockdown of CEACAM6 with CEACAM6-specific small interfering RNA in colorectal cancer cells attenuated invasivity (35%); conversely, the overexpression of CEACAM6 increased invasiveness. CONCLUSIONS: CEACAM6 is significantly upregulated in colon cancer tissues and is closely associated with poor prognosis, indicating that CEACAM6 might be used as a tumor biomarker and a potential therapeutic target for colon cancer.
BACKGROUND:Carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6) inhibits anoikis and affects the malignant phenotype of cancer cells. In this study, we analyzed CEACAM6 as a gene that is highly upregulated in colon cancer tissues, and examined the assertion that CEACAM6 might be a suitable candidate tumor marker for the diagnosis of colon cancer. METHODS:CEACAM6 gene expression in human colon tissues was performed by tissue microarray and analyzed using RT-PCR (each of normal and tumor tissue, n=40) and immunohistochemical and clinicopathological (colon cancerpatients, n=143) analyses. RESULTS:CEACAM6 transcriptional and translational levels were significantly upregulated in humantumor tissues compared to non-tumor regions, and clinicopathological analysis revealed a significant correlation between CEACAM6 protein expression and Dukes' stage (p<0.001). High expression levels of CEACAM6 were significantly associated with lower overall survival (p<0.001) and shorter recurrence-free survival (p<0.001). We demonstrated that knockdown of CEACAM6 with CEACAM6-specific small interfering RNA in colorectal cancer cells attenuated invasivity (35%); conversely, the overexpression of CEACAM6 increased invasiveness. CONCLUSIONS:CEACAM6 is significantly upregulated in colon cancer tissues and is closely associated with poor prognosis, indicating that CEACAM6 might be used as a tumor biomarker and a potential therapeutic target for colon cancer.
Authors: Kinga Bednarek; Magdalena Kostrzewska-Poczekaj; Marcin Szaumkessel; Katarzyna Kiwerska; Julia Paczkowska; Ewa Byzia; Adam Ustaszewski; Joanna Janiszewska; Anna Bartochowska; Reidar Grenman; Malgorzata Wierzbicka; Krzysztof Szyfter; Maciej Giefing; Malgorzata Jarmuz-Szymczak Journal: Am J Cancer Res Date: 2018-07-01 Impact factor: 6.166
Authors: Madeeha Aqil; Kim M Elseth; Ashok Arjunakani; Philip Nebres; Courtney P Amegashie; Devang H Thanki; Premal B Desai; James A Radosevich Journal: Tumour Biol Date: 2014-12-11
Authors: Nicole E McNeil; Hesed M Padilla-Nash; Floryne O Buishand; Yue Hue; Thomas Ried Journal: Genes Chromosomes Cancer Date: 2016-11-01 Impact factor: 5.006
Authors: Jennifer Raisch; Emmanuel Buc; Mathilde Bonnet; Pierre Sauvanet; Emilie Vazeille; Amélie de Vallée; Pierre Déchelotte; Claude Darcha; Denis Pezet; Richard Bonnet; Marie-Agnès Bringer; Arlette Darfeuille-Michaud Journal: World J Gastroenterol Date: 2014-06-07 Impact factor: 5.742
Authors: Hiroto Nishino; Hannah M Hollandsworth; Siamak Amirfakhri; Yoshihiko Tashiro; Jun Yamamoto; Michael A Turner; Thinzar M Lwin; Bernhard B Singer; Robert M Hoffman; Michael Bouvet Journal: J Surg Res Date: 2021-04-10 Impact factor: 2.417